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Introduction
CM is a prevalent, disabling neurological disorder.
OnabotulinumtoxinA is the only approved therapy spe-
cifically for CM. In patients who do not respond to the
first onabotulinumtoxinA injection cycle, it is unclear
whether subsequent injections cycles will be effective.
Objective
To determine the proportion of first-time responders
with chronic migraine (CM) who demonstrate a clini-
cally meaningful response to onabotulinumtoxinA in the
first 3 treatment cycles of the PREEMPT clinical
program.
Design/methods
PREEMPT (two phase 3 studies: 24-week, double-blind,
placebo-controlled, parallel-group phase, followed by 32-
week, open-label phase) evaluated onabotulinumtoxinA
for prophylaxis of headaches in CM (≥15 days/month
with headache lasting ≥4 hours/day). Patients were ran-
domized (1:1) to onabotulinumtoxinA (155-195U) or
placebo every 12 weeks. We evaluated 50% responder
rate for three treatment cycles across multiple efficacy
variables. This rate exceeds the previously suggested
clinically meaningful response rate of 30% in patients
with CM.1
Results
Pooled analyses demonstrated high responder rates
among onabotulinumtoxinA-treated patients (n=688)
after Treatment Cycle 1 in frequency of headache days
(49.3% of patients), moderate/severe headache days
(53.0%), and cumulative hours of headache on headache
days (54.2%) and a 21;5-point improvement in HIT-6
(56.3%). After Treatment Cycle 2, an additional 11.3-
14.5% of patients who did not respond to Treatment
Cycle 1 became responders. With a third treatment, an
additional 7.4-10.3% of patients became responders.
Conclusions/relevance
These data demonstrate that a high proportion of ona-
botulinumtoxinA-treated patients are responsive (50%
improvement) to the first treatment cycle, and patients
who were not responders to the first cycle may become
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